Clinical & Translational Oncology SCIE

国际简称：CLIN TRANSL ONCOL 参考译名：临床和转化肿瘤学

主要研究方向：肿瘤学-医学非预警期刊审稿周期：约2.2月

《临床和转化肿瘤学》(Clinical & Translational Oncology)是一本由Springer International Publishing出版的以肿瘤学-医学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q2 JCR分区
287 年发文量
2.8 IF影响因子
未开放 是否OA
42 H-index
2000 创刊年份
Monthly 出版周期
English 出版语言

Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.

[ 查看全部 ]

投稿咨询加急咨询

投稿热线：400-888-7501

Clinical & Translational Oncology期刊信息

ISSN：1699-048X
出版语言：English
是否OA：未开放
E-ISSN：1699-3055
出版地区：SPAIN
是否预警：否
出版商：Springer International Publishing
出版周期：Monthly
创刊时间：2000
开源占比：0.1792
Gold OA文章占比：21.58%
OA被引用占比：0.2184...
出版国人文章占比：0.25
出版撤稿占比：0
研究类文章占比：75.61%

Clinical & Translational Oncology CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

6.2

0.837

0.79

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q2	121 / 404	70%
大类：Medicine 小类：Cancer Research	Q2	101 / 230	56%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Clinical & Translational Oncology中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	4区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学	4区

Clinical & Translational Oncology JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q2	157 / 322	51.4%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q3	177 / 322	45.19%

Clinical & Translational Oncology历年数据统计

影响因子

中科院分区

Clinical & Translational Oncology中国学者发文选摘

1、Tumor mutational burden and efficacy of chemotherapy in lung cancer
Author: Song, Juan; Yan, Yu; Chen, Cuicui; Li, Jiamin; Ding, Ning; Xu, Nuo; Bao, Hairong; Zhang, Xin; Hong, Qunying; Zhou, Jian; Shao, Yang W.; Song, Yuanlin; Tong, Lin; Hu, Jie

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 173-184. DOI: 10.1007/s12094-022-02924-6
2、The correlations between psychological distress, cognitive impairment and quality of life in patients with brain metastases after whole-brain radiotherapy
Author: Yao, Senbang; Zuo, He; Li, Wen; Cai, Yinlian; Zhang, Qianqian; Pang, Lulian; Jing, Yanyan; Yin, Xiangxiang; Cheng, Huaidong

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 207-217. DOI: 10.1007/s12094-022-02927-3
3、A research review of experimental animal models with myelodysplastic syndrome
Author: Chen, Gen-Wang; Chen, Mei-Na; Liu, Lei; Zheng, Yu-Yu; Wang, Jin-Peng; Gong, Si-Si; Huang, Rong-Fu; Fan, Chun-Mei; Chen, Yue-Zu

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 105-113. DOI: 10.1007/s12094-022-02931-7
4、The pleiotropic mode and molecular mechanism of macrophages in promoting tumor progression and metastasis
Author: Zhang, Xingxing; Bai, Wenxiu; Hu, Lisha; Ha, Hualan; Du, Yuelin; Xiong, Wei; Wang, Hongbo; Shang, Panfeng

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 91-104. DOI: 10.1007/s12094-022-02932-6
5、Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy
Author: Chen, Dujuan; Qin, Hongyue; Deng, Guangchuan; Wang, Qi; Wang, Haiyong; Liu, Xijun

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 226-235. DOI: 10.1007/s12094-022-02936-2
6、DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer
Author: Li, Yuan; Liao, Leen; Kong, Lingheng; Jiang, Wu; Tang, Jinghua; Han, Kai; Hou, Zhenlin; Zhang, Chenzhi; Zhou, Chi; Zhang, Linjie; Sui, Qiaoqi; Xiao, Binyi; Mei, Weijian; Xu, Yanbo; Yu, Jiehai; Hong, Zhigang; Pan, Zhizhong; Ding, Peirong

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 218-225. DOI: 10.1007/s12094-022-02930-8
7、The crucial role of LncRNA MIR210HG involved in the regulation of human cancer and other disease
Author: Lu, Juan; Zhu, Danhua; Zhang, Xiaoqian; Wang, Jie; Cao, Hongcui; Li, Lanjuan

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 1, pp. 137-150. DOI: 10.1007/s12094-022-02943-3
8、Targeted delivery of nuclear targeting probe for bladder cancer using cyclic pentapeptide c(RGDfK) and acridine orange
Author: Qin, Jiaxin; Liang, Qing; Wang, Guangyue; Hao, Lin; Liu, Xing; Wang, Xinlei; Hu, Zhengxiang; Fang, Gaochuan; Xue, Liang; Zhao, Yan; Li, Rui; Lv, Qian; Wen, Jiling; Yang, Guosheng; Han, Conghui; Shi, Zhenduo

Journal: CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; Vol. 25, Issue 2, pp. 375-383. DOI: 10.1007/s12094-022-02938-0